Scientific article
English

Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study

Published in

Joint, Bone, Spine, vol. 83, no. 2, p. 191-197

Publication date

2016

Abstract

Rituximab (RTX) is increasingly used in patients with refractory rheumatoid arthritis (RA) and other severe autoimmune diseases (AID). In practice, many clinicians are reluctant to prescribe RTX in patients with low B-cell counts because of the presumed risk of infection. The aim of this study was therefore to investigate whether B-cell counts before treatment or retreatment with RTX predict the occurrence of infections.

Keywords

  • Adult
  • Aged
  • 80 and over
  • Autoimmune Diseases/drug therapy/immunology
  • B-Lymphocytes/immunology
  • Female
  • Humans
  • Immunologic Factors/adverse effects/immunology/therapeutic use
  • Infection/chemically induced/etiology/immunology
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Risk Factors
  • Rituximab/adverse effects/immunology/therapeutic use
  • Young Adult

Citation (ISO format)

LAZAROU, Ilias et al. Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study. In: Joint, Bone, Spine, 2016, vol. 83, n° 2, p. 191–197. doi: 10.1016/j.jbspin.2015.05.012

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

1297-319X
548views
0downloads

Technical informations

Creation

04/09/2017 14:44:00

First validation

04/09/2017 14:44:00

Update

03/02/2025 13:00:29

Status update

03/02/2025 13:00:29

Last indexation

03/02/2025 13:03:50
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated